Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: None, pure observational study.
- Who it may be relevant to
- Registry conditions: Cerebral Hemorrhage, Acute Lobar Haematoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment. Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis. An equivalent marker has also been described in gadolinium-enhanced MRI. By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.
Interventions
- Other None, pure observational study
None, pure observational study
Primary outcome measures
- Presence of spot sign on gadolinium MRI [Time frame: baseline]
- Morphologic description of gadolinium MRI spot sign [Time frame: baseline]
- Quantitative description of gadolinium MRI spot sign [Time frame: baseline]
Secondary outcome measures (2)
- association of spot sign with hematoma expansion on follow-up CT [Time frame: Baseline]
- Association with the underlaying pathology [Time frame: Baseline]
Eligibility criteria
Inclusion criteria
- Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
- Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.
Exclusion criteria
- Patient refusing to participate
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- CHU de Nîmes — Nîmes
Identifiers
NCT: NCT06781034 · Local/2024/TP-02